Elizabeth M. Jaffee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Elizabeth M. Jaffee has a total of 774 co-authors. Here are the top co-authors by number of shared publications:
- Won Jin Ho
Johns Hopkins University 2 Baltimore, MD
194 shared publications - James M. Leatherman
Sidney Kimmel Comprehensive Cancer Center 8 Baltimore, MD
186 shared publications - Daniel J. Zabransky
Sidney Kimmel Comprehensive Cancer Center 1 Department of Oncology Johns Hopkins University School of Medicine, Baltimore, Maryland
165 shared publications - Jacquelyn W. Zimmerman
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland
165 shared publications - Samantha Guinn
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland
163 shared publications - Elana Judith Fertig
Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, USA
149 shared publications
Latest Publications
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Clinical, Genomic, and Spatial Transcriptomic Features of Pancreatic Adenosquamous Carcinoma Support Subtype-Specific Therapeutic Strategies
Survival outcomes in ASQ versus PDAC
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Clinical, Genomic, and Spatial Transcriptomic Features of Pancreatic Adenosquamous Carcinoma Support Subtype-Specific Therapeutic Strategies
Survival outcomes in ASQ versus PDAC
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Clinical, Genomic, and Spatial Transcriptomic Features of Pancreatic Adenosquamous Carcinoma Support Subtype-Specific Therapeutic Strategies
Pathologic and molecular features
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Clinical, Genomic, and Spatial Transcriptomic Features of Pancreatic Adenosquamous Carcinoma Support Subtype-Specific Therapeutic Strategies
Pathologic and molecular features
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Clinical, Genomic, and Spatial Transcriptomic Features of Pancreatic Adenosquamous Carcinoma Support Subtype-Specific Therapeutic Strategies
Neoadjuvant chemotherapy regimens in spatial transcriptomics cohort
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Clinical, Genomic, and Spatial Transcriptomic Features of Pancreatic Adenosquamous Carcinoma Support Subtype-Specific Therapeutic Strategies
Neoadjuvant chemotherapy regimens in spatial transcriptomics cohort
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Clinical, Genomic, and Spatial Transcriptomic Features of Pancreatic Adenosquamous Carcinoma Support Subtype-Specific Therapeutic Strategies
Full statistics for pathway enrichment analysis of ASQ versus PDAC
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Clinical, Genomic, and Spatial Transcriptomic Features of Pancreatic Adenosquamous Carcinoma Support Subtype-Specific Therapeutic Strategies
Full statistics for pathway enrichment analysis of ASQ versus PDAC
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Clinical, Genomic, and Spatial Transcriptomic Features of Pancreatic Adenosquamous Carcinoma Support Subtype-Specific Therapeutic Strategies
Tissue sampling sites in FoundationOne cohort
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Clinical, Genomic, and Spatial Transcriptomic Features of Pancreatic Adenosquamous Carcinoma Support Subtype-Specific Therapeutic Strategies
Tissue sampling sites in FoundationOne cohort
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Clinical, Genomic, and Spatial Transcriptomic Features of Pancreatic Adenosquamous Carcinoma Support Subtype-Specific Therapeutic Strategies
Full statistics for differential gene expression analysis of ASQ versus PDAC
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Clinical, Genomic, and Spatial Transcriptomic Features of Pancreatic Adenosquamous Carcinoma Support Subtype-Specific Therapeutic Strategies
Full statistics for differential gene expression analysis of ASQ versus PDAC
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Clinical, Genomic, and Spatial Transcriptomic Features of Pancreatic Adenosquamous Carcinoma Support Subtype-Specific Therapeutic Strategies
Full statistics for differential gene expression analysis of squamous versus glandular regions in ASQ
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Clinical, Genomic, and Spatial Transcriptomic Features of Pancreatic Adenosquamous Carcinoma Support Subtype-Specific Therapeutic Strategies
Full statistics for differential gene expression analysis of squamous versus glandular regions in ASQ
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Clinical, Genomic, and Spatial Transcriptomic Features of Pancreatic Adenosquamous Carcinoma Support Subtype-Specific Therapeutic Strategies
Full statistics for pathway enrichment analysis of squamous versus glandular regions in ASQ
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Clinical, Genomic, and Spatial Transcriptomic Features of Pancreatic Adenosquamous Carcinoma Support Subtype-Specific Therapeutic Strategies
Full statistics for pathway enrichment analysis of squamous versus glandular regions in ASQ
- 22 September 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (11) , 2217-2222
Targeting RAS for Pancreatic Cancer Interception
Summary: Multiple strategies to target RAS are now available to treat pancreatic cancer. As pancreatic precancers also have KRAS mutations, these tools hold great promise for cancer interception.
- 22 September 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (11) , 2217-2222
Targeting RAS for Pancreatic Cancer Interception
Summary: Multiple strategies to target RAS are now available to treat pancreatic cancer. As pancreatic precancers also have KRAS mutations, these tools hold great promise for cancer interception.
- 4 September 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (36)
Synthetic long peptide and DNA personalized cancer vaccines induce robust neoantigen-specific T cell responses in pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is unresponsive to standard immunotherapies despite harboring cancer neoantigens capable of eliciting T cell responses. We completed two phase 1 clinical trials (NCT03956056 and NCT03122106) evaluating safety and immunogenicity of synthetic long peptide (SLP) and DNA personalized cancer vaccines (PCVs). PCVs were administered after resection and adjuvant chemotherapy. Tumor/normal whole-exome sequencing, RNA sequencing, and pVACtools were used to identify and prioritize candidate PCV neoantigens. PCVs were well tolerated without any grade ≥3 adverse events. Neoantigen-specific responses were demonstrated by interferon-γ enzyme-linked immunospot and intracellular cytokine staining. Expanded T cell receptor clonotypes were sequenced and transduced into autologous peripheral blood mononuclear cells to confirm neoantigen specificity. When compared with a contemporaneous institutional propensity-matched cohort, PCV patients demonstrated a trend toward prolonged median overall survival (4.4 versus 3.5 years, log-rank P = 0.23). Overall, PDAC PCVs are safe and feasible and elicit polyclonal T cell responses, linking prioritized cancer neoantigens to functional antitumor immunity.
- 4 September 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (36)
Synthetic long peptide and DNA personalized cancer vaccines induce robust neoantigen-specific T cell responses in pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is unresponsive to standard immunotherapies despite harboring cancer neoantigens capable of eliciting T cell responses. We completed two phase 1 clinical trials (NCT03956056 and NCT03122106) evaluating safety and immunogenicity of synthetic long peptide (SLP) and DNA personalized cancer vaccines (PCVs). PCVs were administered after resection and adjuvant chemotherapy. Tumor/normal whole-exome sequencing, RNA sequencing, and pVACtools were used to identify and prioritize candidate PCV neoantigens. PCVs were well tolerated without any grade ≥3 adverse events. Neoantigen-specific responses were demonstrated by interferon-γ enzyme-linked immunospot and intracellular cytokine staining. Expanded T cell receptor clonotypes were sequenced and transduced into autologous peripheral blood mononuclear cells to confirm neoantigen specificity. When compared with a contemporaneous institutional propensity-matched cohort, PCV patients demonstrated a trend toward prolonged median overall survival (4.4 versus 3.5 years, log-rank P = 0.23). Overall, PDAC PCVs are safe and feasible and elicit polyclonal T cell responses, linking prioritized cancer neoantigens to functional antitumor immunity.